Optum sues former executive for working for competitor company run by Atul Gawande

Healthcare Finance | January 25, 2019

Optum has sued former executive David William Smith for going to work for Amazon, Berkshire-Hathaway and JPMorgan Chase, breaking his non-compete agreement. Optum has filed for a temporary restraining order to prevent Smith from working for the company it calls "ABC." Smith, former vice president of Product/Corporate Strategy, has opposed the request for a TRO in a motion filed Tuesday in Massachusetts District Court. The lawsuit shows the threat that the ABC company poses for the healthcare industry. Optum's parent company, UnitedHealth Group, also controls the nation's largest health insurance company, UnitedHealthcare.

Spotlight

According to the CDC, 32 percent of US national health expenditures go to hospitals. In Europe, the breakdown is closer to 40-45 percent. This suggests spending in the US is more decentralized to small clinics and practices compared to Europe.


Other News
FUTURE OF HEALTHCARE

Gozio Health Announces Financial Partnership with Morgan Stanley Expansion Capital

Gozio Health | March 31, 2022

Gozio Health, an industry-leading location-aware mobile patient engagement platform, announced the closing of an investment from funds managed by Morgan Stanley Expansion Capital. The investment round will be used to accelerate Gozio's growth and sets the stage for a long-term financial partnership. “We are at a turning point in healthcare where digital strategy is not only a competitive differentiator for health systems but is foundational to positive consumer experiences. An effective digital platform can enhance engagement with patients, prevent revenue leakage and increase overall patient satisfaction. With the strong support of Morgan Stanley, Gozio is poised to substantially ramp up efforts to equip health systems with the kind of robust, extensible platform needed to optimize digital engagement.” Joshua Titus, Founder and CEO of Gozio Gozio’s mobile patient engagement solution provides health systems with a turnkey digital front door, offering a unified platform which integrates HCIT applications, including physician directories, appointment scheduling, EHR and patient record access, into an easy-to-use mobile application. Gozio’s solution also leverages the Company’s patented, industry-leading wayfinding technology to provide real-time, turn-by-turn directions to patients and staff. “The consumerization of healthcare is driving hospitals and health systems to increasingly focus on patient experience and engagement. Gozio offers a solution that helps patients not only navigate the physical network of the health system, but also provides patients mobile access to the services, information and applications necessary to engage patients in their own care,” said Melissa Daniels, Managing Director at Morgan Stanley Expansion Capital. “We believe Gozio’s digital front door and wayfinding technology provide a compelling value proposition by enhancing the personal end-to-end consumer experience within the network of the health system. We are thrilled to be partnering with Joshua and the Gozio team to support the Company as it continues on its growth trajectory.” Gozio will use the funding to expand its client base among leading health systems, grow its client services and engineering teams, and advance the extensibility of its platform to support a digital health ecosystem. About Gozio Health Gozio Health offers an end-to-end, customizable digital health platform exclusively for healthcare systems. Gozio’s extensible mobile platform enables seamless consumer interactions and provides an anytime, anywhere connection to patients that improves their overall experience and access to care. Popular patient engagement features include patented indoor wayfinding with turn-by-turn navigation, virtual visits, physician directories, appointment scheduling, access to electronic health records, Urgent Care and Emergency Department wait-times, and extensive analytics capabilities. Gozio customers surveyed in a 2021 KLAS Research Emerging Technology Spotlight report found 100% satisfaction and improved experience for patients and staff. About Morgan Stanley Expansion Capital Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. Morgan Stanley Expansion Capital targets growth equity and credit investments within technology, healthcare, consumer, digital media and other high-growth sectors. For over three decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 200 companies, leveraging the global brand and network of Morgan Stanley.

Read More

HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions. NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System Current Procedural Terminology code analysis/applications and health economic analysis. “Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”, Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world. Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.” NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark. Additional target markets would be Taiwan and other Asian countries. About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Read More

FUTURE OF HEALTHCARE

Mental Health Provider Meru Health collaborates with Tech-Savvy Health Insurance Company Evry Health To Deliver Outcomes-Based Mental Healthcare

MERU HEALTH | January 18, 2022

Meru Health, the most comprehensive mental health solution in the market with industry-leading outcomes, and Evry Health, a modern business-to-business health insurance company announced today that they will partner on delivering Meru Health's solution to Evry Health's members in Dallas, Texas starting January 2022. The Meru Health online mental health solution will be embedded as part of Evry Health's tailored wellness plans that come at no cost to the employer or their employees. These specialized, optional wellness solutions provide a wide range of resources, tools and rewards that are different from other health insurance plans, including benefits such as mental health support through Meru Health. Members will be recommended to the program based on pre-screening criteria as well as Evry Health's data analysis. For example, if Evry Health receives a claim for cancer screening and oncologist claims, this is a flag to proactively loop the member into Meru Health's mental health program and support cycles. The partnership will focus on delivering outcomes-based mental healthcare and it rewards members for following their personalized care pathways. A member who completes Meru Health's 12-week Therapy program can get up to $100 reward for doing so. "This is a completely new way of delivering mental healthcare and we are proud to partner with Meru Health to together change how the system works," said Chris Gay, Evry Health CEO. "Focusing on outcomes is the way mental healthcare – and healthcare in general – should be delivered now and in the future. We are confident our members will get the best possible value-based care, and see their mental health improve as they go through the Meru Health program." Incentivizing members to take care of their mental health can lead to major cost savings down the line. According to data from BCBS, people with major depression are on average nearly 30 percent less healthy than those without depression. This decrease in overall health translates into increased costs: a depressed person has $6,390 more healthcare costs than nondepressed people every year. Evry Health incentivizes participants to focus on better mental health through its voluntary wellness plans. Rewards are deposited to an Evry Health Reward Card that members use like any other credit card. Meru Health is focused on delivering the best long- and short-term outcomes in the market. After program completion, 75% of people are in depression or anxiety symptom remission and 85% of people show clinically significant improvement, measured on industry standard PHQ-9 (depression) and GAD-7 (anxiety) scales. The Meru Health Program is one of only digital mental health interventions with published research that shows that these treatment gains last 12 months after the end of treatment. "We could not be more excited to partner Evry Health, who is changing health insurance just like we are transforming mental healthcare. Together we can really deliver patient-centric care that ensures that people prioritize their mental health. Health plans and employers would benefit a lot focusing more on outcomes. The question we should be asking is are people getting better and staying better after the treatment? I believe trailblazers like Evry Health will be a role model in the industry to start focusing more on care outcomes." Kristian Ranta, the CEO of Meru Health About Meru Health Meru Health is setting the new standard in mental healthcare with the most comprehensive online solution that combines licensed therapists and psychiatrists, a smartphone-based treatment program, biofeedback training, anonymous peer support, and habit-changing activities for sleep, nutrition, and more. The company is committed to evidence-based care and has published groundbreaking clinical outcomes with Stanford, Harvard, and UC Davis that show promising clinical effectiveness and lasting results. Meru Health offers a convenient, accessible, side-effect-free mental health treatment option in contrast to the standard of care in the U.S. today. Meru Health partners with major health insurance providers like Cigna, Humana, and Moda Health, as well as leading businesses that want to provide best-in-class mental health care for their employees or members. About Evry Health Headquartered in Dallas, Evry Health is not your standard health plan. We're on a mission to make healthcare affordable, transparent and high quality again by providing expanded benefits at an affordable price, lowering premiums by up to 20%. We're building the health insurance we've always wanted for ourselves, with a high-tech, mobile-first experience focused on helping people live better, healthier lives.

Read More

Spotlight

According to the CDC, 32 percent of US national health expenditures go to hospitals. In Europe, the breakdown is closer to 40-45 percent. This suggests spending in the US is more decentralized to small clinics and practices compared to Europe.

Resources